Pfizer Inc. (NYSE: PFE) and Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced the companies have entered into a definitive agreement under which Pfizer will acquire GBT, a biopharmaceutical company dedicated to the discovery, development and delivery of life-changing treatments that provide hope to underserved patient communities, starting with sickle cell disease (SCD).
Pfizer to acquire Global Blood Therapeutics for $5.4 billion to enhance presence in rare hematology
August 8, 2022
Related blog posts
New drug shows promise for fighting both COVID-19 and cancer
November 15, 2022